- Home
- NBBK vs NUVB Comparison
NBBK vs NUVB Comparison
Compare NBBK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- NUVB
- Stock Information
- Founded
- NBBK 1892
- NUVB 2018
- Country
- NBBK United States
- NUVB United States
- Employees
- NBBK N/A
- NUVB N/A
- Industry
- NBBK
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- NUVB Health Care
- Exchange
- NBBK Nasdaq
- NUVB Nasdaq
- Market Cap
- NBBK 824.1M
- NUVB 679.9M
- IPO Year
- NBBK N/A
- NUVB N/A
- Fundamental
- Price
- NBBK $17.97
- NUVB $1.75
- Analyst Decision
- NBBK Buy
- NUVB Strong Buy
- Analyst Count
- NBBK 1
- NUVB 6
- Target Price
- NBBK $22.00
- NUVB $8.33
- AVG Volume (30 Days)
- NBBK 255.8K
- NUVB 2.9M
- Earning Date
- NBBK 04-23-2025
- NUVB 03-06-2025
- Dividend Yield
- NBBK N/A
- NUVB N/A
- EPS Growth
- NBBK 365.22
- NUVB N/A
- EPS
- NBBK 1.07
- NUVB N/A
- Revenue
- NBBK $160,607,000.00
- NUVB $7,873,000.00
- Revenue This Year
- NBBK N/A
- NUVB $47.99
- Revenue Next Year
- NBBK N/A
- NUVB $551.81
- P/E Ratio
- NBBK $16.89
- NUVB N/A
- Revenue Growth
- NBBK 23.80
- NUVB N/A
- 52 Week Low
- NBBK $13.26
- NUVB $1.66
- 52 Week High
- NBBK $21.05
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- NBBK 37.89
- NUVB 34.21
- Support Level
- NBBK $18.16
- NUVB $1.85
- Resistance Level
- NBBK $19.19
- NUVB $2.04
- Average True Range (ATR)
- NBBK 0.42
- NUVB 0.12
- MACD
- NBBK -0.04
- NUVB -0.01
- Stochastic Oscillator
- NBBK 12.90
- NUVB 13.74
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).